Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765983 | 1.00 | EPHX1 (0.38) | EPHX1NAAASHBGADH1AADH1C | |
| SCHEMBL6383370 | 1.00 | EPHX1 (0.38) | EPHX1NAAASHBGADH1AADH1C | |
| SCHEMBL2582250 | 0.97 | — | — | |
| SCHEMBL125380 | 0.92 | — | — | |
| SCHEMBL127042 | 0.86 | — | — | |
| SCHEMBL6384799 | 0.83 | NAAA (0.35) | EPHX1NAAASHBGADH1ACYP1A2 | |
| SCHEMBL5321699 | 0.83 | NAAA (0.35) | EPHX1NAAASHBGADH1ACYP1A2 | |
| SCHEMBL6381348 | 0.83 | NAAA (0.35) | EPHX1NAAASHBGADH1ACYP1A2 | |
| SCHEMBL6379898 | 0.80 | NAAA (0.33) | EPHX1NAAACYP1A2 | |
| SCHEMBL2357695 | 0.80 | NAAA (0.41) | EPHX1NAAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090209602-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
| EP-2035397-A1 | CHEMICAL COMPOUNDS | Astra Zeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2032546-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Astra Zeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007141502-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007141538-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| EP-1200428-B1 | SUBSTITUTED BENZOXAZOLES | BASF AG (DE) | 2003-04-16 | — | — | EP | disclosed |
| US-6528455-B1 | Post or preemergence herbicides such as 3-(4-chloro-2-fluoro -5-(1-methoxycarbonyl-1-vinyloxy)phenyl)-1-methyl-6-trifluoro methyl-2,4-pyrimidinedione | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-04 | — | — | US | disclosed |
| US-6482774-B1 | Substituted (4-brompyrazole-3-yl) benzazoles | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-19 | — | — | US | disclosed |
| EP-0915853-B1 | SUBSTITUTED 3-PHENYL PYRAZOLES | BASF AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1076660-B1 | SUBSTITUTED (4-BROMPYRAZOLE-3-YL)BENZAZOLES | BASF AG (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-6383986-B1 | USE AS HERBICIDES, DESICCANTS OR DEFOLIANTS AND PLANT SAFENING AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-07 | — | — | US | disclosed |
| CN-1302298-A | Substituted (4-brompyrazole-3-yl) indole | BASF AG (DE) | 2001-07-04 | — | — | CN | disclosed |
| US-6232470-B1 | AGRICULTURE | BASF AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | disclosed |
| US-6197973-B1 | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-06 | — | — | US | disclosed |
| CN-1244865-A | Substituted pyrazole-3-yl benzazoles | BASF AK (DE) | 2000-02-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | EPHX1 1786/4885NAAA 1518/4885SHBG 2374/4885 |
| US-20090209602-A1 | CHEMICAL COMPOUNDS | DGAT1, ACAT2, DGAT2 | EPHX1 1189/4885NAAA 137/4885SHBG 2348/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | EPHX1 2212/4885NAAA 1469/4885SHBG 2141/4885 |
| US-20100160397-A1 | OXAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | DGAT1, ACAT1, DGAT2 | EPHX1 695/4885NAAA 215/4885SHBG 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.